349 related articles for article (PubMed ID: 16254335)
1. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.
Hong GK; Gulley ML; Feng WH; Delecluse HJ; Holley-Guthrie E; Kenney SC
J Virol; 2005 Nov; 79(22):13993-4003. PubMed ID: 16254335
[TBL] [Abstract][Full Text] [Related]
2. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.
Jones RJ; Seaman WT; Feng WH; Barlow E; Dickerson S; Delecluse HJ; Kenney SC
Int J Cancer; 2007 Sep; 121(6):1274-81. PubMed ID: 17520680
[TBL] [Abstract][Full Text] [Related]
3. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
4. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.
Hong GK; Kumar P; Wang L; Damania B; Gulley ML; Delecluse HJ; Polverini PJ; Kenney SC
J Virol; 2005 Nov; 79(22):13984-92. PubMed ID: 16254334
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
9. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
10. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
11. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
Rowe M; Young LS; Crocker J; Stokes H; Henderson S; Rickinson AB
J Exp Med; 1991 Jan; 173(1):147-58. PubMed ID: 1845872
[TBL] [Abstract][Full Text] [Related]
13. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
Baiocchi RA; Caligiuri MA
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241
[TBL] [Abstract][Full Text] [Related]
14. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines.
Tsai SC; Lin SJ; Chen PW; Luo WY; Yeh TH; Wang HW; Chen CJ; Tsai CH
Blood; 2009 Jul; 114(1):109-18. PubMed ID: 19417211
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Feng WH; Kenney SC
Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192
[TBL] [Abstract][Full Text] [Related]
16. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood.
Ohga S; Ishimura M; Yoshimoto G; Miyamoto T; Takada H; Tanaka T; Ohshima K; Ogawa Y; Imadome K; Abe Y; Akashi K; Hara T
J Clin Virol; 2011 May; 51(1):31-7. PubMed ID: 21377409
[TBL] [Abstract][Full Text] [Related]
17. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
18. A review of the cytomorphology of Epstein-Barr virus-associated malignancies.
Michelow P; Wright C; Pantanowitz L
Acta Cytol; 2012; 56(1):1-14. PubMed ID: 22236740
[TBL] [Abstract][Full Text] [Related]
19. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
